

HR 2009

Removing Barriers to Allergy Diagnostic Testing Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 1, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 2, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2009>

Sponsor

Name: Rep. Clarke, Yvette D. [D-NY-9]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (19 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Upton, Fred [R-MI-6]	R · MI		Apr 1, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Apr 4, 2019
Rep. Moulton, Seth [D-MA-6]	D · MA		Apr 9, 2019
Rep. Peters, Scott H. [D-CA-52]	D · CA		Apr 9, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Apr 9, 2019
Rep. Pocan, Mark [D-WI-2]	D · WI		Apr 10, 2019
Rep. Engel, Eliot L. [D-NY-16]	D · NY		Apr 12, 2019
Rep. Krishnamoorthi, Raja [D-IL-8]	D · IL		Apr 12, 2019
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Apr 25, 2019
Rep. Gonzalez, Vicente [D-TX-15]	D · TX		Apr 25, 2019
Rep. Meadows, Mark [R-NC-11]	R · NC		May 1, 2019
Rep. Johnson, Bill [R-OH-6]	R · OH		May 15, 2019
Rep. Himes, James A. [D-CT-4]	D · CT		Jun 18, 2019
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Jun 19, 2019
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		Sep 29, 2020
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Sep 29, 2020
Rep. Tonko, Paul [D-NY-20]	D · NY		Sep 30, 2020
Rep. DeGette, Diana [D-CO-1]	D · CO		Nov 17, 2020
Rep. Veasey, Marc A. [D-TX-33]	D · TX		Nov 19, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 2, 2019
Ways and Means Committee	House	Referred to	Apr 1, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 2246	Related bill	Jul 24, 2019: Read twice and referred to the Committee on Finance.

Summary (as of Apr 1, 2019)

Removing Barriers to Allergy Diagnostic Testing Act of 2019

This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare.

Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.

Actions Timeline

- **Apr 2, 2019:** Referred to the Subcommittee on Health.
- **Apr 1, 2019:** Introduced in House
- **Apr 1, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Apr 1, 2019:** Referred to the Subcommittee on Health.